Lack of association between paraoxonase 1 Q192R polymorphism and multiple sclerosis in relapse phase: A case-control study

Clinical Biochemistry

Volumn 44, Issue 10-11, 2011, Pages 795-798

  Moghtaderi, Ali ^a   Hashemi, Mohammad ^a   Sharafaddinzadeh, Naser ^b   Dabiri, Soroosh ^a   Moazeni Roodi, Abdolkarim ^a   Ramroodi, Noorollah ^a   Zolfaghari, Moloud ^a  

^a ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Jondishapoor University of Medical Sciences   (Iran)

Author keywords

Arylesterase; Multiple sclerosis; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; CHOLESTEROL; CORTICOSTEROID; INTERFERON; TRIACYLGLYCEROL;

ADULT; ARTICLE; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; POPULATION DISTRIBUTION; PRIORITY JOURNAL; RELAPSE; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AMINO ACID SUBSTITUTION; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; DEMOGRAPHY; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 79958774783     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.04.010     Document Type: Article

References (27)

1. Durrington P.N., Mackness B., Mackness M.I. Paraoxonase and atherosclerosis. Arterioscl Throm Vas 2001, 21(4):473-480.
2. Shin B.S., Oh S.Y., Kim Y.S., Kim K.W. The paraoxonase gene polymorphism in stroke patients and lipid profile. Acta Neurol Scand 2008, 117(4):237-243.
3. Voetsch B., Benke K.S., Damasceno B.P., Siqueira L.H., Loscalzo J. Paraoxonase 192 Gln ->Arg polymorphism-an independent risk factor for nonfatal arterial ischemic stroke among young adults. Stroke 2002, 33(6):1459-1464.
4. Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., Furlong C.E. The molecular-basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993, 3(1):73-76.
5. Davies H.G., Richter R.J., Keifer M., Broomfield C.A., Sowalla J., Furlong C.E. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996, 14(3):334-336.
6. Ranade K., Kirchgessner T.G., Iakoubova O.A., Devlin J.J., DelMonte T., Vishnupad P., et al. Evaluation of the paraoxonases as candidate genes for stroke-Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke. Stroke 2005, 36(11):2346-2350.
7. Mackness B., Durrington P.N., Mackness M.I. Human serum paraoxonase. Gen Pharmacol 1998, 31(3):329-336.
8. Jamroz-Wisniewska A., Beltowski J., Stelmasiak Z., Bartosik-Psujek H. Paraoxonase 1 activity in different types of multiple sclerosis. Mult Scler 2009, 15(3):399-402.
9. Sidoti A., Antognelli C., Rinoldi C., DAngelo R., Dattola V., Girlanda P., et al. Glyoxalase I A111E, paraoxonase 1 q192R and L55M polymorphisms: susceptibility factors of multiple sclerosis?. Mult Scler 2007, 13(4):446-453.
10. Aviram M. HDL-associated paraoxonase 1 (PON1) and dietary antioxidants attenuate upoprotein oxidation, macrophage foam cells formation and atherosclerosis development. Pathophysiol Haemo T 2006, 35(1-2):146-151.
11. Ferretti G., Bacchetti T., Principi F., Di Ludovico F., Viti B., Angeleri V.A., et al. Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paraoxonase activity. Mult Scler 2005, 11(6):677-682.
12. Etemadifar M., Janghorbani M., Shaygannejad V., Ashtari F. Prevalence of multiple sclerosis in Isfahan, Iran. Neuroepidemiology 2006, 27:39-44.
13. Ghandehari K., Riasi H.R., Nourian A., Boroumand A.R. Prevalence of multiple sclerosis in north east of Iran. Mult Scler 2010, 16(12):1525-1526.
14. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001, 50(1):121-127.
15. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005, 58(6):840-846.
16. Hashemi M., Moazeni-Roodi A.K., Fazaeli A., Taheri M., Sandoughi M., Bardestani G.R., et al. The L55M polymorphism of paraoxonase-1 is a risk factor for rheumatoid arthritis. Genet Mol Res 2010, 9(3):1735-1741.
17. Hashemi M., Moazeni-Roodi A.K., Fazaeli A., Sandoughi M., Bardestani G.R., Kordi-Tamandani D.M., et al. Lack of association between paraoxonase-1 Q192R polymorphism and rheumatoid arthritis in southeast Iran. Genet Mol Res 2010, 9(1):333-339.
18. Koch M., Ramsaransing G.S., Arutjunyan A.V., Stepanov M., Teelken A., Heersema D.J., et al. Oxidative stress in serum and peripheral blood leukocytes in patients with different disease courses of multiple sclerosis. J Neurol 2006, 253(4):483-487.
19. Jamroz-Wisniewska A., Bartosik-Psujek H., Beltowski J., Stelmasiak Z. Paraoxonase (PON) 1 activity in multiple sclerosis patients. Eur J Neuro 2007, 14:281.
20. Jamroz-Wisniewska A., Bartosik-Psujek H., Beltowski J., Stelmasiak Z. Paraoxonase 1 activity does not change in stable and progressive type of multiple sclerosis but decreases during relapse of the disease. J Neurol 2008, 255:141-142.
21. Martinez C., Garcia-Martin E., Benito-Leon J., Calleja P., Diaz-Sanchez M., Pisa D., et al. Paraoxonase 1 polymorphisms are not related with the risk for multiple sclerosis. Neuromol Med 2010, 12:217-223.
22. Mackness M.I., Arrol S., Abbott C.A., Durrington P.N. Is paraoxonase related to atherosclerosis. Chem Biol Interact 1993, 87(1-3):161-171.
23. Koch M., Hering S., Barth C., Ehren M., Enderle M.D., Pfohl M. Paraoxonase 1 192 Gln/Arg gene polymorphism and cerebrovascular disease: interaction with type 2 diabetes. Exp Clin Endocr Diab 2001, 109(3):141-145.
24. Aviram M., Rosenblat M., Billecke S., Erogul J., Sorenson R., Bisgaier C.L., et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radical Biol Med 1999, 26(7-8):892-904.
25. Cakatay U., Kayali R., Uzun H. Relation of plasma protein oxidation parameters and paraoxonase activity in the ageing population. Clin Exp Med 2008, 8(1):51-57.
26. Imai Y., Morita H., Kurihara H., Sugiyama T., Kato N., Ebihara A., et al. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 2000, 149(2):435-442.
27. Van Lenten B.J., Wagner A.C., Navab M., Fogelman A.M. Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6. J Biol Chem 2001, 276(3):1923-1929.